Kornimate/medical-research-clean huggingface dataset:
outcomes of a novel treatment decision of patients with esophageal and head and neck carcinoma synchronously

Conditions: Head and Neck Cancer; Esophageal Cancer Stage

Summary: to summarise the outcomes of a treatment decision of patients with superficial esophageal carcinoma synchronously associated with head and neck cancer, that is endoscopic treatment for the superficial esophageal carcinoma plus surgery of the head and neck carcinoma.

as a same risk factor, such as heavy drinking and smoking, patients with head and ncek carcinoma are always suffering from synchronous esophageal squamous cell carcinoma. previous studies illustrated that many patients with multiple esophageal lesions of early stage. in clinical practice, those patients are treated by extensive surgical resection of total pharyngo-laryngo-esophagectomy plus free jejunum interposition or gastric tube, then followed by chemoradiotherapy as standard treatment, resulting in a low quality of life for the patients, and due to the above mentioned disadvantages, many patients with synchronous superficial esophageal squamous cell carcinoma and head and neck carcinoma refused the surgery treatment. our aims is to summarize the the outcomes of endoscopic treatment for the superficial esophageal carcinoma plus surgery of head and neck carcinoma.

Eligibility criteria:
inclusion criteria: 1. patients with head and ncek carcinoma associated with synchronous superficial esophageal squamous cell carcinoma. 2. patients agree to be treated with esophageal endoscopic submucosal dissection firstly, then accept surgery of head and neck carcinoma. exclusion criteria: 1. patients refuse a endoscopic submucosal dissection or surgery. 2. patients with sever systemic disease, such as sever cardiopulmonary disease, renal failure and impaired blood coagulation. 3. obstruction of the pharynx leading to a failure of insertion of endoscopy. 4. patients with an advanced esophageal carcinoma evaluated by endoscopy.

Keywords: head and neck cancer esophageal cancer endoscopic submucosal dissection quality of life median survival time
evaluation of the efficacy of stiripentol (diacomit) as monotherapy for the treatment of primary hyperoxaluria

Conditions: Primary Hyperoxaluria

Summary: evaluation of the efficacy of stiripentol (diacomit) as monotherapy for the treatment of primary hyperoxaluria. pilot clinical study, open, prospective and multicenter.


Eligibility criteria:
inclusion criteria: * patient with primary hyperoxaluria type 1, 2 or 3, diagnosed according to standard methods * having at least one molar ratio \[oxaluria / creatinuria\] greater than 0.08 since diagnosis * having glomerular filtration rate ≥ 45 ml / min / 1.73m2 * age ≥ 6 months * having read, or whose parents have read, the information note and signed the consent form. for children, if their level of understanding allows, their assent will also be sought * proficient enough, or whose parents or legal representatives have sufficient mastery, the french language to read, understand and complete study documents * affiliate or beneficiary of a social security scheme * ability to respect the protocol, including treatment, and can be followed regularly in the study * for pubertal patients, contraception deemed effective by the investigator or abstinence exclusion criteria: * introduction, discontinuation or dose modification of vitamin b6 or potassium citrate treatment within 4 weeks prior to the inclusion visit * consumption of jelly candies and / or dark chocolate in the week preceding the study * patient having a kidney and / or liver transplant * presence of a clinically significant acute or chronic pathology, other than primary hyperoxaluria, that may interfere with the evaluation of the study results according to the investigator * during biological or physical examinations, presence of significant anomaly (s) inconsistent with participation in the study according to the investigator * history of severe allergy, asthma, skin rash or hypersensitivity to a drug * treatment affecting hepatic metabolism (cimetidine, ketoconazole, fluconazole, itraconazole, phenytoin, rifampicin, rifabutin) in progress or taken during the month preceding the start of the study * treatment affecting the renal tubule (probenecid, β-lactams, ...) in progress or taken during the last two weeks preceding the start of the study * presence of a pathology or treatment that, according to the investigator, renders the subject unfit * contraindications to stiripentol as defined in the current smpc (hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the smpc, history of psychosis in the form of delusional episodes) * pregnant or lactating woman * patient under guardianship * patient concurrently participating in another clinical trial or exclusion period following a previous trial
effect of gabapentin on sleep and opioid use following rotator cuff repair

Conditions: Rotator Cuff Tears

Summary: the goal of this clinical trial is to compare the effects of gabapentin in patients undergoing rotator cuff repair surgery. the main question it aims to answer is whether gabapentin can improve postoperative pain and sleep quality. participants in this study will be randomized to either take gabapentin after surgery or a placebo after surgery.

perioperative gabapentin use has been established in prior literature to decrease postoperative opioid use; however, all of these studies have evaluated gabapentin given by an anesthesia team in the immediate pre- or intraoperative period. no known literature exists regarding scheduled post-operative oral gabapentin use in regards to pain control and opioid use. sleep quality still tends to be a frequent concern associated with rotator cuff injury and shoulder surgery in general. the added known benefit of somnolence or drowsiness, in addition to aid in sleep, with use of gabapentin may also contribute to improved sleep quality following rotator cuff repair.

Eligibility criteria:
inclusion criteria: * diagnosed traumatic or degenerative rotator cuff tear undergoing primary arthroscopic repair * between the ages of 18 and 65 years old exclusion criteria: * chronic pre-operative narcotic pain medication use * undergoing superior capsular reconstruction / balloon interposition etc * \ 65 y/o * bilateral rotator cuff tear * currently taking prescribed sleep-aid medications * history of fibromyalgia or chronic pain syndrome * pain management patient * narcolepsy diagnosis * diagnosis of cervical radiculopathy * reported non-shoulder pain interfering with sleep

Keywords: rotator cuff repair gabapentin opioid use
pharmacogenetic of doxorubicin in hcc.

Conditions: Hepatocellular Carcinoma

Summary: the study included 81 hcc patients, both male and female. prior to being assessed for eligibility, each recruited patient with hcc received a comprehensive review of their medical history, physical status, and laboratory results. every research participant take part in the experiment and provided written informed consent.

all patients had their baseline viral indicators for hbv and hcv evaluated. additionally, blood samples were taken for genotyping. all patients underwent evaluations of their kidney, liver, and alpha fetoprotein (afp) functions, as well as their complete blood count (cbc), at both the baseline and follow-up appointments. to evaluate the efficacy of tace, triple pelvic abdominal ct scans were performed both prior to and one month later. using triphasic pelviabdominal ct, patients who achieved complete response (cr) were monitored for up to 13 months following chemotherapy in order to identify recurrence. follow-up appointments were planned to identify patients responces or any negative effects.

Eligibility criteria:
inclusion criteria: 1. when diagnosing the patient with hcc, the guidelines provided by the american association for the study of liver diseases (aasld) were adhered to. 2. be above 20 years old. 3. individuals with intact organs. 4. there is no cure for hcc in surgery, microwave treatment, or radiofrequency ablation. exclusion criteria: 1. the patients refused to sign the formal consent. 2. be more than 75 years old. 3. there is a notable case of portal vein thrombosis. 4. spreads beyond the liver. 5. encephalopathy of the liver. 6. present sickness.
evaluation of pre-deployment device-to-artery relative axial motion in coronary catheterizations

Conditions: Cardiovascular Disease

Summary: the cyclic movement of the heart and the coronary arteries induces relative axial movement between the artery and a pre-deployed intra-luminal stent which may cause malpositioning. using a new imaging algorithm to indicate the position of a stent in patients undergoing percutaneous coronary intervention (pci), the investigators will measure the pre-deployment relative, intra-luminal stent axial movement in the different coronary arteries to facilitate the precise deployment site.


Eligibility criteria:
inclusion criteria: * patients undergoing routine pci exclusion criteria: * unstable patients
patient acceptable symptomatic state and minimal clinically important difference of the fatigue in multiple sclerosis (sedif_sep)

Conditions: Multiple Sclerosis

Summary: fatigue is the most common symptom and the most disabling symptom of multiple sclerosis, and its inefficient management can be a source of multiple consultations (increase in health costs) and a reduction in productivity (work stoppages). hence the need to define the most effective therapeutic strategy to reduce fatigue in multiple sclerosis. one of the aims of this project is to provide clinical indicators that can serve as evaluation criteria for determining the most effective fatigue management strategy in multiple sclerosis. the primary objective of the study is to determine the minimal clinically important difference (mcid) and the patient acceptable symptomatic state (pass) for fatigue in multiple sclerosis. the source population consists of all people with multiple sclerosis living in lorraine and registered in the lorraine registry of multiple sclerosis (relsep).

two-year patient follow-up is planned with data collection at 0, 12 and 24 months. in addition to data already collected as part of the establishment and monitoring of the relsep registry, more specific data for this study will be collected at 0, 12 and 24 months by self-questionnaires sent to patients' homes.

Eligibility criteria:
inclusion criteria: * patient \> or = 18 years old * patient with multiple sclerosis according to mc donald's diagnostic criteria * patient registered in the relsep registry * being able to fill out a questionnaire * person who has received complete information on the organization of the research and who has not objected to the exploitation of his data exclusion criteria: * patients no longer residing in lorraine * bedridden patients * patients under guardianship, curatorship or safeguard of justice * patients with other serious pathologies with heavy treatments (eg cancer under chemotherapy or radiotherapy).
a study to evaluate formulations and food effect on gsk364735 in healthy subjects.

Conditions: HIV Infection; Infection, Human Immunodeficiency Virus

Summary: this study is a two-part study. part one is designed to see how different formulations of gsk364735 are absorbed in the body and to see how food affects how gsk364735 is absorbed in the body. part two is designed to see how repeat dosing affects how gsk364735 is absorbed in the body.


Eligibility criteria:
inclusion criteria: * the subject is healthy with no clinically significant problems identified by the physician. * females of non-childbearing potential and males surgically sterile or agrees to birth control. * body mass index (bmi) of 19-29.9 (kg/m2). exclusion criteria: * as a result of the physical examination, lab results the investigator considers the subject unfit for the study. * blood pressure and electrocardiogram is not normal * a history of alcohol or illicit drug abuse. * tobacco use within 3 months. * positive for hepatitis b surface antigen, hepatitis c antibody or hiv antibody. * current use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements. * has participated in a clinical trial within 30 days prior to the first dose of study medication. * donated a pint of blood within a 56 day period. * history of allergy to study drug.

Keywords: hiv repeat dose pharmacokinetics bioavailability single-dose food effect
effect of different electric muscle stimulation in patients with severe sepsis and respiratory failure

Conditions: Severe Sepsis; Acute Respiratory Failure; Muscle Hypotonia; Inflammation; Weakness

Summary: rationale : electric muscle stimulation reduced critical-illness related weakness in patients with severe sepsis and septic shock. but optimal protocol of the stimulation in unknown. hypothesis: focal muscle contraction may improved the muscle power and have systemic anti-inflammatory via cytokine secretion . the difference of electricity used in upper limb or lower limb stimulation may lead to different effect. study design: stratified randomized parallel control study, comparing biceps, quadriceps electric muscle stimulation vs. non-stimulation group. participant: adult patients with severe sepsis and acute respiratory failure requiring mechanical ventilation. intervention: daily stimulation of bilateral biceps or quadriceps by programmed electric devices 32 minutes, 5 days/week outcome: 1. primary outcome: ventilator-dependent days 2. secondary outcome: change of hand drip muscle power/interleukin-1b/interleukin-6/interleukin-8/tnf-alpha

background : severe sepsis and septic shock remain top cause of admission to intensive care unit. muscle weakness was found in 70-100% patients with severe sepsis and septic shock because of critical-illness induced polyneuropathy and myopathy. previous study revealed electric muscle stimulation (ems) could reduce such muscle weakness and mechanical ventilator-dependent days. hypothesis: different electricity may be needed for minimal contraction of upper or lower limb because of their muscle size. induced muscle contraction may lead to myokine secretion and beneficial metabolic and anti-inflammatory effect. stimulation on quadriceps may be better than on biceps. participant: adult(older than 20 years-old) patients with severe sepsis.septic shock and acute respiratory failure post mechanical ventilation. design: stratified ( gender and age \>50 years-old) randomized parallel 3 arms study. intervention: daily stimulation of biceps of quadriceps after third days in intensive care unit. programmed electric stimulation device ( helex 573 model, strength aggressive. mode, 45-55hz 32 minutes per day, voltage 30-70ma)

Eligibility criteria:
inclusion criteria: * severe sepsis or septic shock patients with acute respiratory failure more than 3 days * adult patients( age\>20 years-old) exclusion criteria: * skin wound/infection near the site of muscle stimulation * acute myocardial infarction within 7 days * pregnant women * uncontrolled epilepsy * no spontaneous breath because of central or cervical spinal neuropathy

Keywords: electric muscle stimulation respiratory failure sepsis interleukin 6 interleukin 15
healthy habits, healthy girls preventing unhealthy weight gain

Conditions: Overweight; Obesity

Summary: the purpose of this study is to evaluate the impact of a multicomponent school-based intervention based on bandura's social cognitive theory targeting healthy eating and physical activity for high school adolescent girls from low-income communities in the city of são paulo, brazil.

the "healthy habits, healthy girls" is a 6-month multi-component school-based intervention developed in reference to social cognitive theory and includes: (1) enhanced physical education classes (2x/week and delivered by a physical education teacher), (2) break/lunch-time physical activity sessions (the participating girls will encourage younger girls to make physical activity during break and/or lunch-time. this session will only happen after 3 months of enhanced physical education classes, so the girls will be able to pass their knowledge for the others), (3) nutrition and physical activity handbooks with 10 health messages (lessons to be done at home and their family); (4) 4 parent newsletters; (5) food and physical activity diaries for self-monitoring; (6) text-messages using a group application for more interaction and social support; and (7) 10 weekly nutrition and physical activity key messages (delivered by a nutrition and dietetics bachelor degree and/or physical education teacher during break). the intervention will be evaluated using a randomised controlled trial in 10 public schools in the city of são paulo, brazil (5 control and 5 intervention) and based on the 10 weekly key messages: (1) eat fruit and vegetables daily; (2) do physical activity respecting your limits; (3) eat a healthy breakfast every day; (4) do physical activity with your family and friends; (5) control the portion size you eat during meals - and sit while you are eating; (6) reduce your sitting time during school break, after the school period and on the weekends; (7) have less "junk food" for meals/snacks and munch less; (8) identify the excuses for not practicing pa; (9) drink water and substitute sodas and artificial juices for water, homemade natural fruit juices and coconut water, and; (10)make family meals.

Eligibility criteria:
inclusion criteria: - adolescent girls from low-income backgrounds enrolled in high schools of the city of são paulo, brazil. exclusion criteria: * adolescent boys * adolescents from middle and high income backgrounds * pregnant

Keywords: adolescent randomized controlled trial eating behavior physical activity sedentary lifestyle
phase 2 study of temozolomide to treat poor risk / refractory acute myeloid leukemia

Conditions: Leukemia, Myeloid

Summary: open-label, non-randomized, parallel assignment, phase 2 trial assessing the safety and efficacy of distinct temozolomide treatment regimens for patients with aml and poor prognosis

this is a single institution phase 2 clinical trial evaluating the efficacy, safety, and tolerability of tailored temozolomide therapy for patients with acute myeloid leukemia (aml) and poor risk features. patients will be assigned to 1 of 2 parallel treatment groups based on their agat promoter region methylation status, as determined by pcr. patients achieving a complete remission after 1 to 2 cycles of chemotherapy will be eligible to receive up to an additional 5 cycles of temozolomide of 5 or 19 days, depending on the methylation status of the agat promoter (consolidation phase).

Eligibility criteria:
inclusion criteria: 1. patients must have histologically or cytologically confirmed acute myeloid leukemia, as defined by the who classification. 2. patients must be considered unfit for conventional induction chemotherapy, unwilling to receive such treatment or have evidence of disease relapse or refractory disease. 3. for patients who have received no prior conventional chemotherapy, one of the following must be present: * poor risk cytogenetics (complex abnormalities, deletions of chromosome 7 or 5, 11q23 abnormalities, inv\[3\]) * secondary leukemia (prior hematologic disorder or therapy-related leukemia). 4. age \> 60 years of age. 5. life expectancy of greater than 3 months. 6. ecog performance status greater than 2. 7. patients must have normal organ and marrow function as defined below: 8. adequate hepatic function: total bilirubin 1.5mg/dl, ast(sgot)/alt(sgpt) 2.5 x institutional upper limit of normal. 9. adequate renal function: serum creatinine within normal institutional limits or calculated creatinine clearance \> 60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal. 10. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: 1. patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin c) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. 2. patients may not be receiving any other investigational agents. 3. history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or dtic 4. history of gastrointestinal disease or significant bowel resection that could interfere with drug absorption. 5. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 6. prior allogeneic stem cell transplantation. 7. inability to swallow tablets 8. prior radiation up to more than 25% of bone marrow.
ct indexes of emphysema and airways in healthy volunteers: normal values; relations with gender, height and weight

Conditions: Healthy

Summary: various indexes have been proposed to quantify both pulmonary emphysema and airways disease on chest ct scans. it is unknown whether these indexes should be consider in absolute values or as compared to predicted normal values. the purposes of the present study is thus : a) to measure these indexes at ct in healthy volunteers; b) to investigate their relations with gender, height and weight.

87 healthy volunteers performed consecutively a low-dose chest ct scan and pulmonary function tests: 1. on chest ct scans, indexes reflecting pulmonary emphysema and airways measurements have been computed by using dedicated softwares. each of our three readers performed two reading sessions. relative area of lung parenchyma with attenuation value less than -960 hounsfield units; luminal area and wall thickness in third and fourth generations airways were recorded. 2. pulmonary function tests were performed: vital capacity, forced vital capacity , functional residual capacity, total lung capacity, residual volume, forced expiratory volume in one second, and diffusion lung capacity for carbon monoxide were recorded (either in absolute values and percentage of predicted values). ct indexes were compared with gender, height and weight.

Eligibility criteria:
inclusion criteria: * never smoked. * no respiratory infection in the 4 weeks before the begin of the study. * no history of pulmonary resection. * no active malignancy or malignancy of any organ system within the past 5 years. exclusion criteria: * no exclusion criteria

Keywords: emphysema airway remodelling multidetector computed tomography
assessment of the impact of thoracic outlet syndromes on the performance at work

Conditions: Thoracic Outlet Syndrome

Summary: thoracic outlet syndrome may associate neurologic, arterial and venous symptoms. the responsibility of repetitive movements and postural factors has been mentioned for long. some tasks are hard to perform, and it seemed interesting to assess the consequences of this syndrome on the work capacity by a questionnaire, at the moment of diagnosis by echo-doppler


Eligibility criteria:
inclusion criteria: * a stenosis of at least 80% of arterial stenosis at echo-doppler examination during abduction-retropulsion of the arm * actually employed or having been employed exclusion criteria: * cognitive or mental impairment * illiteracy * visual impairment * patients having been diagnosed with fibromyalgia, chronic fatigue syndrome or ehler-danlos syndrome

Keywords: thoracic outlet syndrome performance at work
ledderhose disease - long term effects of radiotherapy treatment. ledrad lte - study

Conditions: Ledderhose Disease

Summary: the aim of the ledrad lte study is to determine the current complaints, late side effects and satisfaction of patients who were treated with radiotherapy for ledderhose disease at least two years ago.


Eligibility criteria:
patients treated with radiotherapy for ledderhose disease at the umcg at least 2 years ago

Keywords: radiotherapy pain side effect satisfaction